{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-316041","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2026-07-24T20:01:26+00:00","discovered_at":"2026-07-24T20:04:00.644090+00:00","generated_at":"2026-07-24T20:04:13.463597+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MannKind gets FDA approval for Furoscix ReadyFlow; raises $50M in private placement","bullets":["FDA approved Furoscix ReadyFlow (furosemide injection) for edema in adults with heart failure or chronic kidney disease.","Private placement of 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, led by Frazier Life Sciences.","Gross proceeds ~$50M; net proceeds to fund $45M CVR payment triggered by FDA approval and for general corporate purposes.","Pre-funded warrants have $0.01 exercise price, no expiration, subject to 19.99% beneficial ownership limitation.","Company agreed to file resale registration statement within 30 days of closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-316041","json":"https://secwatch.observer/filing/0001193125-26-316041.json","markdown":"https://secwatch.observer/filing/0001193125-26-316041.md","text":"https://secwatch.observer/filing/0001193125-26-316041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/0001193125-26-316041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/d63182d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-24T20:04:13.463597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}